Capital for Cures
For investors

Royalties from all six areas of life sciences

We work with asset managers and royalty funds that buy royalties or lend against them. We find royalties, prepare the information you need to review them and introduce you to the holders.

How we work with asset managers and royalty funds

  1. 1 Find

    We search filings, patent records and our network across six areas of life sciences, and approach the holders.

  2. 2 Prepare

    We collect the licence terms, the payment history and available sales data for each royalty, and identify the consents needed from partners and lenders.

  3. 3 Bundle

    Where royalties are too small to fund one by one, we group them into portfolios large enough to fund.

  4. 4 Introduce

    We introduce holders to asset managers and royalty funds, which carry out their own due diligence, agree terms with the holder and make their own investment decisions.

We also audit royalty books that asset managers and royalty funds already hold. More on portfolio audits

Our own AI models read the documents where royalties are written down

Most royalties are never announced. They sit in licence agreements, company filings, court records and patent assignments. Our models, trained on licensing deals, extract the terms and map who pays royalties to whom.

Sources
What we read
  • Company filings in the US, Japan, Korea and China
  • Court records, where royalty rates are sometimes unredacted
  • Patent records and changes of ownership
  • Approved products in all six areas
Our models
What we extract
  • Royalty rate, tiers and caps
  • Territory and term
  • Who pays whom, across agreements
What we find
Royalties that are hard to find
  • Royalties that were never announced, such as a large company paying a small private licensor
  • Royalty tails: payments that continue after a cap is reached or the main patents expire
  • Royalties on one region, such as Japan or Europe
  • Smaller royalties, including those held by universities and hospitals
  • Royalties outside pharma

Where royalties are financed today

In pharma, holders regularly sell royalties or borrow against them. In the other five areas the instrument works the same way, but few deals are made public.

Outside pharma and vaccines: almost 30% of sales, about 2% of royalty financings
Each area's share of annual sales, compared with its share of royalty financings (number of deals, 2020 to 2025)
Annual salesabout $2.3tn
71%
22%
Royalty financings, 2020 to 2025131 deals
98%
AreaSalesShareDeals
Pharma and vaccinesAbout $1.6tn71%128
MedtechOver $500bn22%2
Crops and seedsAbout $120bn5%0
Animal healthAbout $39bn2%1

Sales show where royalties can arise; the share of sales that carries a royalty varies by area. Sales are for the latest year available, 2022 to 2024, and rounded; shares use $500bn for medtech. The pharma figure includes vaccines other than for COVID-19. Animal health covers only the 20 largest companies, so its share is understated. Digital health has no reliable figure for global sales and is left out. Deals are those publicly disclosed and listed in the tracker, classified by Capital for Cures by the product area of the royalty.

Capital for Cures, royalty intelligenceSources: IQVIA Institute, Kalorama, AgbioInvestor, AgriBusiness Global, HealthforAnimals, Gibson Dunn Royalty Finance Tracker; classification by Capital for Cures

Talk to us about a royalty or a portfolio

Sebastian Gensior
sebastian@capitalforcures.com
Michał Czarnuch
michal@capitalforcures.com
Book a call
Capital for Cures AG, Schoffelgasse 3, 8001 Zürich, Switzerland